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BACKGROUND According to recent studies, the presence of peri-
strut low intensity area (PLIA) detected by optical coherence to-
mography (OCT) has been described as a potential marker of
abnormal neointimal healing such as continuous inﬂammation,
ﬁbrin deposition, and extracellular matrix accumulation. However,
the impact of PLIA presence on clinical events and its risk factors
remain unknown.
METHODS From the Kobe University OCT registry, we enrolled a
total of 382 lesions treated with coronary stents (BMS: n¼23, 1st
generation DES: n¼186, 2nd generation DES: n¼249) from 289 pa-
tients that underwent mid-term follow-up OCT 6-12 months after
stent implantation. In addition to standard OCT parameters, PLIA
was evaluated with the deﬁnition of homogenous low-intensity area
around a stent strut without signiﬁcant signal attenuation behind
the area. Clinical follow-up was performed to evaluate target lesion
revascularization (TLR) for a median duration of 2.71.9 years after
stenting.
RESULTS PLIA was identiﬁed in 205 lesions (54%) on the follow-up
OCT (PLIA+ group). The remaining 177 lesions did not exhibit PLIA
(PLIA- group). The incidence of smoking habit, unstable angina
pectoris or acute myocardial infarction, BMS and paclitaxel eluting
stents use was signiﬁcantly higher in the PLIA+ group. Also, the
rate of dyslipidemia and dual antiplatelet therapy at the timing of
follow-up OCT was signiﬁcantly lower in the PLIA+ group than
PLIA- group. In multivariate logistic analysis, smoking habit, BMS
and paclitaxel eluting stents use were independently associated
with the presence of PLIA (odds ratio [OR]: 1.64, P¼0.026, OR:
25.77, P¼ 0.002, OR: 5.10, P<0.001 respectively). Moreover, pa-
tients with PLIA had a higher incidence of TLR during the clinical
follow-up (PLIA+: 16.6% vs. PLIA-: 1.7%, P<0.01 Figure A).
Multivariate logistic regression analysis showed that , in addition
to statin use, the presence of PLIA was an independent risk
factor for TLR (OR: 7.36, P ¼ 0.001). A landmark analysis at one
year after stent implantation showed that the presence of PLIA
was associated with higher incidence of late TLR (TLR>1year)
after stenting (Figure B).CONCLUSIONS The presence of PLIA on mid-term OCT imaging was
associated with TLR after stent implantation. Detailed stent assess-
ment by mid-term follow-up OCT may help predict future stent failure
in patients with coronary artery disease.
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BACKGROUND Severe mitral regurgitation (MR) is the most preva-
lent valve disorder. It is associated with a high morbidity and need
for hospitalization, and a 5yr mortality >50%. Options for man-
agement in the high surgical risk population are limited. Trans-
catheter mitral valve implantation (TMVI) is a promising alternative
to conventional surgery in high-risk patients. The Global Feasibility
Trial aims to evaluate the Tendyne TMVI prosthesis in a population
of patients with severe mitral regurgitation at high risk for surgical
repair.
METHODS The trial is a prospective, non-randomised, open-label
study designed to evaluate the safety and efﬁcacy of a novel mitral
valve prosthesis implanted via an intercostal, trans-apical route. The
device consists of a D-shaped outer frame, a circular inner frame and a
symmetrical porcine pericardial trileaﬂet valve that is deployed
within the mitral annulus and tethered to the apex of the left
ventricle. The valve can be fully recaptured, repositioned, and if
necessary, fully retrieved. Up to 30 patients with severe, symptomatic
MR who are considered poor candidates for surgical valve repair will
be included in the Feasibility Trial. Patients are considered ineligible
for the trial if they have LVEF<30%, LVEDD >7.0cm, prior mitral or
aortic valve surgery, severe coronary disease, heart failure requiring
inotropic support, severe tricuspid valve regurgitation or severe RV
dysfunction. Anatomic suitability is evaluated by transthoracic and
transesophageal echo, and full cycle CT angiography. The primary
efﬁcacy endpoint for the trial is MR grade<2 at 90days. The primary
safety endpoint is a composite of freedom from cardiovascular death,
stroke, myocardial infarction, or surgical intervention for valve-
related dysfunction.
RESULTS To date, 6 patients (5M, 1F; age 75.83.4yrs) have been
treated at two study sites. All patients had severe (4þ) MR (5 sec-
ondary, 1 primary MR), and all were symptomatic (3pts NYHA class III,
3pts NYHA class IV). The LVEF was 40.811.0% (range 30-61%) and
the mean STS score was 8 (range 2-16). In 5 patients, the device was
successfully deployed with no residual MR, no paravalvular leak, MV
gradient 2.20.7mmHg, and no adverse events. In one pt, deployment
of the device resulted in a signiﬁcant LV outﬂow gradient and hypo-
tension. The device was removed without adverse sequelae. Each
pt was discharged home between post-operative day 5 and day 7.
All remain alive. The 5 with successful implants are all in NYHA class I
or II.
CONCLUSIONS The preliminary results from this Feasibility Trial
suggest that the Tendyne device can be used to effectively treat
MR with a low peri-procedural complication rate in a high-risk
population. 30day outcomes for pts enrolled in the trial will be
presented.
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